CSIR-CFTRI Mysuru Conducts Extensive Health Checkup Camp Using AI and Machine Learning for Precision Healthcare

The CSIR Health Cohort project is a five-year initiative covering CSIR laboratories nationwide. Over 10,000 employees, including retirees and spouses, have been enrolled for extensive health checkups, including phlebotomy, imaging, and scanning. The data collected will be analyzed using AI and machine learning to develop personalized risk predictions for various diseases. The project aims to identify genetic, biochemical, and lifestyle risk factors and serve as a national resource for precision healthcare.

The CSIR Health Cohort project, a five-year initiative spanning across CSIR laboratories nationwide, is set to revolutionize the landscape of personalized healthcare in India. Over 10,000 employees, including retirees and their spouses, have been enrolled for extensive health checkups, encompassing phlebotomy, imaging, and scanning. The data collected will be analyzed using advanced AI and machine learning techniques to develop personalized risk predictions for various diseases.

Phase II of the CSIR Health Cohort project was recently inaugurated at the CSIR-CFTRI in Mysuru. The project aims to identify genetic, biochemical, and lifestyle risk factors, serving as a national resource for precision healthcare. Over 300 participants have undergone health check-ups in the Mysuru camp, with the first phase completed in February 2023 [1].

The project, CSIR Phenome India Health Cohort Project - Phase II Camp, involves extensive biochemical and omics investigations, including genomics, proteomics, metabolomics, cytokines profile, and telomere length measurement. Imaging and scanning techniques such as spirometry, ECG, body composition, liver scan, and oscillometry are also being employed. The data will be stored at the CSIR Biobank at CSIR-IGIB, Delhi, under strict anonymity protocols [1].

The project is coordinated by Shantanu Sengupta, Chief Scientist at CSIR-IGIB, Delhi. The second phase of the testing camp included a health and nutritional questionnaire regarding food frequency, highlighting the increasing prevalence of lifestyle disorders due to processed food consumption [1].

The third phase of the project is scheduled for mid-2026, with higher enrollment of subjects expected. The project's strategic use of AI and machine learning approaches positions it at the forefront of developing precision healthcare in India [1].

In parallel, GT Biopharma, Inc. (NASDAQ: GTBP) has initiated Cohort 3 of its Phase 1 dose escalation trial evaluating GTB-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic malignancies. The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and clinical activity of GTB-3650, a second-generation TriKE natural killer (NK) cell engager [2].

Renovaro Inc. (NASDAQ: RENB), leveraging federated learning and biodefense patents, addresses data privacy and drug discovery challenges in biomedical AI. The company's AI-powered zebrafish platform enables rapid neurotoxin countermeasure development, expanding into national security contracts and grants. Despite a $7.3M Q2 2025 loss and a $0.23 stock price, Renovaro targets a $20B biomedical AI market through platform licensing and IP-driven partnerships [3].

References:
[1] https://www.thehindu.com/news/national/karnataka/health-data-at-cftri-mysuru-to-be-analysed-using-ai-and-machine-learning/article69924132.ece
[2] https://www.biospace.com/press-releases/gt-biopharma-advances-into-cohort-3-of-gtb-3650-phase-1-trial-following-safety-review-of-cohort-2
[3] https://www.ainvest.com/news/renovaro-nasdaq-renb-strategic-convergence-ai-biodefense-precision-medicine-2508/